What's Happening?
Niagen Bioscience, a leader in NAD+ science and healthy-aging research, will participate in Canaccord Genuity’s 45th Annual Growth Conference. The company's CEO, Rob Fried, and CFO, Ozan Pamir, are scheduled to engage in a fireside chat and hold one-on-one meetings with institutional investors. The conference, taking place in Boston from August 12 to 14, 2024, will provide a platform for Niagen Bioscience to discuss its advancements in NAD+ boosting solutions. The company is known for its product Niagen, a patented nicotinamide riboside supplement, which is a leading NAD+ booster in the U.S.
AD
Why It's Important?
Niagen Bioscience's participation in the conference underscores its role as a key player in the biotechnology sector, particularly in the field of healthy aging. The company's focus on NAD+ research is significant as it addresses age-related health changes, a growing concern in an aging population. By engaging with investors, Niagen Bioscience aims to attract further investment to support its research and development efforts. This could lead to new innovations in the field, potentially improving health outcomes for older adults and expanding the market for NAD+ supplements.
What's Next?
Following the conference, Niagen Bioscience is expected to continue its efforts in advancing NAD+ research and expanding its product offerings. The company may explore new partnerships and collaborations with research institutions to further its scientific discoveries. Additionally, the outcomes of the investor meetings could influence the company's strategic direction and funding opportunities, potentially leading to accelerated growth and development in the NAD+ supplement market.
